Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes

Cellular Oncology

Volumn 34, Issue 1, 2011, Pages 45-54

  Ku, Ja Lok ^a   Kim, Kyung Hee ^a   Choi, Jin Sung ^a   Jeon, You Kyung ^a   Kim, Sung Hee ^a   Shin, Young Kyoung ^a   Kim, Tae You ^a   Bang, Yung Jue ^a   Kim, Woo Ho ^a   Park, Jae Gahb ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cell line; EGFR gene; Establishment; Lung cancer

Indexed keywords

BETA CATENIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; K RAS PROTEIN; MESSENGER RNA; MITOMYCIN C; MITOXANTRONE RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT; MICROSATELLITE DNA; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DNA FINGERPRINTING; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; SINGLE STRAND CONFORMATION POLYMORPHISM; CELL SHAPE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE LOCUS; GENETICS; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CELL SHAPE; DNA FINGERPRINTING; DNA MUTATIONAL ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC LOCI; HUMANS; LUNG NEOPLASMS; MICROSATELLITE REPEATS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052551566     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-010-0004-6     Document Type: Article

References (35)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M.J. Thun, Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008)
2. H. Shin, K. Jung, Y. Won, J. Park, 2002 Annual Report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. J. Korean Cancer Assoc. 36, 103-114 (2002)
3. M. Sanchez-Cespedes, Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer 40, 111-121 (2003) (Pubitemid 36438711)
4. Y.R. Chen, Y.N. Fu, C.H. Lin, S.T. Yang, S.F. Hu, Y.T. Chen, S.F. Tsai, S.F. Huang, Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25, 1205-1215 (2006)
5. S.W. Han, T.Y. Kim, P.G. Hwang, S. Jeong, J. Kim, I.S. Choi, D. Y. Oh, J.H. Kim, D.W. Kim, D.H. Chung, S.A. Im, Y.T. Kim, J.S. Lee, D.S. Heo, Y.J. Bang, N.K. Kim, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-smallcell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23, 2493-2501 (2005) (Pubitemid 47050839)
6. A.F. Gazdar, H.K. Oie, Re: Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46, 6011-6012 (1986)
7. A.F. Gazdar, H.K. Oie, Cell culture methods for human lung cancer. Cancer Genet. Cytogenet. 19, 5-10 (1986) (Pubitemid 16149765)
8. J.L. Ku, K.A. Yoon, W.H. Kim, Y. Jang, K.S. Suh, S.W. Kim, Y.H. Park, J.G. Park, Establishment and characterization of four human pancreatic carcinoma cell lines. Genetic alterations in the TGFBR2 gene but not in the MADH4 gene. Cell Tissue Res. 308, 205-214 (2002)
9. C.S. Koh, J.L. Ku, S.Y. Park, K.H. Kim, J.S. Choi, I.J. Kim, J.H. Park, S.K. Oh, J.K. Chung, J.H. Lee, W.H. Kim, C.W. Kim, B.Y. Cho, J.G. Park, Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol. Cell. Endocrinol. 264, 118-127 (2007) (Pubitemid 46097308)
10. M.S.Kang, H.J.Lee, J.H.Lee, J.L.Ku, K.P. Lee,M.J. Kelley,Y.J.Won, S.T. Kim, J.G. Park, Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA. Int. J. Cancer 67, 898-902 (1996) (Pubitemid 26348822)
11. M.N. Kitaeva, L. Grogan, J.P. Williams, E. Dimond, K. Nakahara, P. Hausner, J.W. DeNobile, P.W. Soballe, I.R. Kirsch, Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res. 57, 4478-4481 (1997) (Pubitemid 27441048)
12. K. Iwao, S. Nakamori, M. Kameyama, S. Imaoka, M. Kinoshita, T. Fukui, S. Ishiguro, Y. Nakamura, Y. Miyoshi, Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res. 58, 1021-1026 (1998) (Pubitemid 28182473)
13. S.L. Lu, W.C. Zhang, Y. Akiyama, T. Nomizu, Y. Yuasa, Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 56, 4595-4598 (1996) (Pubitemid 26338054)
14. M. Tokumo, S. Toyooka, K. Kiura, H. Shigematsu, K. Tomii, M. Aoe, K. Ichimura, T. Tsuda, M. Yano, K. Tsukuda, M. Tabata, H. Ueoka, M. Tanimoto, H. Date, A.F. Gazdar, N. Shimizu, The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11, 1167-1173 (2005) (Pubitemid 40175767)
15. J.R. Melki, P.C. Vincent, R.D. Brown, S.J. Clark, Hypermethylation of E-cadherin in leukemia. Blood 95, 3208-3213 (2000) (Pubitemid 30321175)
16. T. Hase, R. Yoshimura, M. Matsuyama, Y. Kawahito, S. Wada, K. Tsuchida, H. Sano, T. Nakatani, Cyclooxygenase-1 and -2 in human testicular tumours. Eur. J. Cancer 39, 2043-2049 (2003) (Pubitemid 37297761)
17. C.H. Yang, E. Schneider, M.L. Kuo, E.L. Volk, E. Rocchi, Y.C. Chen, BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol. 60, 831-847 (2000)
18. R. Rajendra, M.K. Gounder, A. Saleem, J.H. Schellens, D.D. Ross, S.E. Bates, P. Sinko, E.H. Rubin, Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9nitrocamptothecin. Cancer Res. 63, 3228-3233 (2003) (Pubitemid 36735876)
19. G. Abbona, M. Papotti, L. Viberti, L. Macri, A. Stella, G. Bussolati, Chromogranin A gene expression in non-small cell lung carcinomas. J. Pathol. 186, 151-156 (1998) (Pubitemid 28467824)
20. A. Chavez-Blanco, L. Taja-Chayeb, L. Cetina, G. Chanona-Vilchis, C. Trejo-Becerril, E. Perez-Cardenas, B. Segura-Pacheco, C. Acuna- Gonzalez, A. Duenas-Gonzalez, Neuroendocrine marker expression in cervical carcinomas of non-small cell type. Int. J. Gynecol. Pathol. 21, 368-374 (2002)
21. J. Kurebayashi, K. Tanaka, T. Otsuki, T. Moriya, H. Kunisue, M. Uno, H. Sonoo, All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J. Clin. Endocrinol. Metab. 85, 2889-2896 (2000) (Pubitemid 32269169)
22. S.P. Langdon, Characterization and authentication of cancer cell lines: an overview. Methods Mol. Med. 88, 33-42 (2004)
23. S. Sekine, T. Shibata, Y. Matsuno, A. Maeshima, G. Ishii, M. Sakamoto, S. Hirohashi, Beta-catenin mutations in pulmonary blastomas: association with morule formation. J. Pathol. 200, 214-221 (2003) (Pubitemid 36748030)
24. M. Hollstein, D. Sidransky, B. Vogelstein, C.C. Harris, p53 mutations in human cancers. Science 253, 49-53 (1991) (Pubitemid 21917115)
25. E.N. Papadakis, D.N. Dokianakis, D.A. Spandidos, p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun. 3, 389-392 (2000)
26. P. Dumont, J.I. Leu, A.C. Della Pietra 3rd, D.L. George,M.Murphy, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365 (2003) (Pubitemid 36278852)
27. T. Hashimoto, Y. Tokuchi, M. Hayashi, Y. Kobayashi, K. Nishida, S. Hayashi, Y. Ishikawa, K. Nakagawa, J. Hayashi, E. Tsuchiya, Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra. Am. J. Pathol. 157, 2133-2141 (2000)
28. C. Ostwald, P. Gogacz, T. Hillmann, J. Schweder, K. Gundlach, G. Kundt, M. Barten, p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int. J. Cancer 88, 82-86 (2000)
29. T. Shimmyo, A. Okada, T. Hashimoto, Y. Kobayashi, Y. Miyagi, Y. Ishikawa, K. Nakagawa, H. Osada, E. Tsuchiya, Etiologic value of p53 mutation spectra and differences with histology in lung cancers. Cancer Sci. 99, 287-295 (2008) (Pubitemid 351228482)
30. S. Hougaard, P. Norgaard, N. Abrahamsen, H.L. Moses, M. Spang-Thomsen, H. Skovgaard Poulsen, Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br. J. Cancer 79, 10051011 (1999)
31. H.S. Kim, H.R. Youm, J.S. Lee, K.W. Min, J.H. Chung, C.S. Park, Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 42, 163-170 (2003)
32. J.G. Park, S.K. Lee, I.G. Hong, H.S. Kim, K.H. Lim, K.J. Choe, W.H. Kim, Y.I. Kim, T. Tsuruo, M.M. Gottesman, MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J. Natl Cancer Inst. 86, 700-705 (1994) (Pubitemid 24138976)
33. M. Miwa, S. Tsukahara, E. Ishikawa, S. Asada, Y. Imai, Y. Sugimoto, Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int. J. Cancer 107, 757-763 (2003) (Pubitemid 37339729)
34. T. Shibata, S. Hanada, A. Kokubu, Y. Matsuno, H. Asamura, T. Ohta, M. Sakamoto, S. Hirohashi, Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci. 98, 985-991 (2007) (Pubitemid 46865381)
35. S.F. Huang, H.P. Liu, L.H. Li, Y.C. Ku, Y.N. Fu, H.Y. Tsai, Y.T. Chen, Y.F. Lin, W.C. Chang, H.P. Kuo, Y.C. Wu, Y.R. Chen, S.F. Tsai, High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195-8203 (2004)